RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

Pfizer has reportedly ended its Phase II/III trials for sisunatovir, a promising RSV candidate acquired with ReViral in a ...

Presentations highlight momentum of Pfizer's portfolio of infectious disease prevention and treatment options NEW YORK, October 8, 2024 - Pfizer Inc ...

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

At the 40-year anniversary of Ghostbusters, Ernie Hudson shares something Americans should gear up to fight this season—with ...

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price ...

Fall means it’s time for just about everybody to get up to date on their flu and COVID-19 vaccines – and a lot of older ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...